189 filings
8-K
MRKR
Marker Therapeutics Inc
12 Jun 24
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
MRKR
Marker Therapeutics Inc
15 May 24
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
4:40pm
8-K
MRKR
Marker Therapeutics Inc
8 Apr 24
Other Events
7:09am
8-K
MRKR
Marker Therapeutics Inc
25 Mar 24
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
6:18pm
8-K
MRKR
Marker Therapeutics Inc
1 Mar 24
Termination of a Material Definitive Agreement
8:02am
8-K
j6w4ce
26 Feb 24
Entry into a Material Definitive Agreement
7:58am
8-K
w437elc65yzz4fmkb
8 Jan 24
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
8:30am
8-K
7aelb02yl7u
11 Dec 23
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
7:35am
8-K
ydwwn 9g4
20 Nov 23
Departure of Directors or Certain Officers
4:37pm
8-K
2ftbz0en8gmfqhs
9 Nov 23
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
5:03pm
8-K
sr1d71yk8oawwe
11 Sep 23
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
7:10am
8-K
o4d6cytod5k9o
14 Aug 23
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:37pm
8-K
uv3yw3xjs aa
7 Aug 23
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
7:22am
8-K
n637zhr8ot76s3 it
10 Jul 23
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
7:09am
8-K
l60 ryii0br0km
3 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
akx5qt
30 Jun 23
Completion of Acquisition or Disposition of Assets
4:05pm
8-K
4w3fw dh9l
26 Jun 23
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
7:14am
8-K
ak8rnc7dmyvazb 0t
12 Jun 23
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
7:09am
8-K
4astx5e
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
2gs0fszi v557
31 May 23
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
6:44am